GlaxoSmithKline announced on Thursday that it has signed a four-year contract with the Biomedical Advanced Research and Development Authority for the provision of its inhalation anthrax treatment, raxibacumab.
In the new contract, GSK will give the United States government 60,000 doses of raxibacumab over a four year period. The estimated value of these shipments total $196 million.